|
 
- 积分
- 3053
- 威望
- 3053
- 包包
- 5595
|
"It's worrying that I could come into work one day and I might not be allowed to do my research because of someone's ideological beliefs rather than the quality of the science."--Jack Mosher at the University of Michigan in Ann Arbor.
- i# `* g7 ^" P2 ]3 K3 M P7 s$ b" v( c) M: f7 S4 H; K( q
"There is a lot of interest in the medical community in India towards storage of stem cells — more than in China or Indonesia."--Steven Fang, group CEO of CordLife, an international stem cell banking firm.
9 Q1 G* L( g& d% u. P/ d8 z% Y4 D2 g' m8 f A, P2 a0 e8 O
"Our goal is try to develop an efficient way to promote cells to making bone. Ideally, we can create a treatment where we don’t have to use protein, deliver genes or modify cells. It can be a form of cell-based therapy."--Tong-Chuan He, associate professor of surgery at the University of Chicago Medical Center." @) j2 e% g) @# H) i% A4 V
0 Q; F1 o B- Z# p" o% U# P"Because of MultiStem's consistent safety profile, potential for off-the-shelf administration, and multiple mechanisms of action, we feel this program could help effectively address the needs of this patient community."Deborah Ladenheim, Ph.D., Vice President of Regulatory Affairs of Athersys.
( N: _5 e/ F& m! d7 v5 V0 h, `/ W9 B! ^+ E( c4 F; d
"It’s a tactical victory. If their goal was to make human embryonic stem-cell research a less attractive option for American researchers, they’ve succeeded, even if they lose their court case."--Murray, president of the Hastings Center, a bioethics research center in Garrison, New York." D7 d5 m! S9 q, X
0 A% ?+ W" S3 @! D: Y2 [ H' c$ v
"We must break with the UK mantra of 'invented here, commercialised elsewhere'...I think there will be a time 20 to 25 years from now where we may well see small molecule, biologic and cells roughly one equal thirds of a large company's portfolio. I don't think it will be the majority, but it will be a significant part."--Chris Mason, BIA-RIG's chair and a professor at University College London's (UCL) regenerative medicine bioprocessing unit.3 _' e5 L0 F/ } p9 L; M! ?
6 F' F! t- Y' m" v* P% i" f"There is a funding gap between the discovery and the translation. People call that the valley of death, and that's what it is. We need to translate and commercialise stem cell therapies, or scientists will move away."--Richard Sykes, chairman of the UK Stem Cell Foundation.6 d- S3 e# j1 V# q i6 ^
7 q* r1 k9 v' j1 h3 }1 d
"Injection of oligodendrocyte progenitor cells directly into the spinal cordlesion is a rational way to attempt to arrest or reverse the structural damage in the spinal cord caused by severe trauma. We are eager to begin evaluating the effects of these cells in subjects with severe spinal cord injuries."--Richard Fessler, M.D., professor of neurological surgery at Northwestern University Feinberg School of Medicine and a surgeon at Northwestern Memorial Hospital.7 i) [% _! m3 t* W1 W" Z) Q1 x
- r0 q% x* j( d/ Z8 q5 |* G* s
"Strategically, what we’re focused on is trying to make sure there is enough therapies advanced to Phase I or Phase II efficacy trials (where) voters of California can judge the performance and decide if they should approve another $3 billion to $5 billion. The voters are going to have to see real evidence."--Bob Klein, architect of Prop. 71 and chairman of California's stem cell research funding agency.1 A* v9 j8 I+ B& C! p$ U& i( w% Q
9 V% H- k9 {2 x/ k2 T# ^ R+ w( B5 O
"We will make sure that the amount of cells we introduce would not be such that it’ll humanise the animal, especially in the brain. So there are safeguards about injecting stem cells into the brain, especially young brain of non—human primates — monkeys and apes and chimpanzees."--Professor Lim Pin, chairman of the Bioethics Advisory Committee of SINGAPORE.) z0 ? K m- |0 S6 V
" w4 d& q6 c, F ~ `, F' l
"Pharma is...looking for new products and the technology is now getting to a stage where it's ready for prime time, it's ready for translation and commercialisation."--Chris Mason, professor of regenerative medicine bioprocessing at UCL.
% J. Y- _2 v. X/ U- W
, V9 q% n/ s, j1 k"It's all very well having a cell that might have an effect, but how are you going to convert that into something that is a marketable therapeutic?"--Michael Hunt, ReNeuron chief exectuive.
2 N0 a. q, ?1 L# z; O+ n H% K. G- u" f: n2 k* N
"Scientists will want to push the boundary, to discover, to invent, to benefit mankind. Rogue scientists are rare and we need rules to rein them in, without stifling genuine research with good potential."--Health Minister Khaw Boon Wan of Singapore., ~$ l; f" D# k
9 ^+ v E" M$ ~
* t2 F1 ]( s& ^5 P" w* u# sThis issue:; @" |2 K$ C4 ^- m/ h3 S* \/ `
|
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 10
查看全部评分
|
发表于 2010-9-30 14:52
